,
Veralox

One Drug Targeting Diabetes, Lupus, And Five Other Indications.

About this Event

Veralox is developing treatments targeting the 12-Lipoxygenase pathway, which has been implicated in immuno-inflammatory diseases including Type 1 Diabetes, Lupus, Heparin-Induced Thrombocytopenia (HIT), and four other indications.

HIT occurs in 300,000 patients in the US alone, which can result in stroke, amputation and death in up to 30% of affected patients.

Veralox’s lead program VLX-1005 targets the root cause of HIT via the 12-Lipoxygenase target and is being developed as a potential treatment. VLX-1005 has received orphan drug and fast-track designation from the FDA and has begun Phase 2 clinical sites that include Stanford and Yale.

Veralox is also in the process of gathering preclinical data internally and via sponsored research for their second program, VLX-2000, an oral medication targeting Type 1 Diabetes, Lupus, and other immune complex diseases.

Watch the webinar with Veralox CEO, Jonathan Mow to hear the full story and hear why Hatteras Venture Partners, Genesys Capital, Sanofi Ventures, JDRF T1D Fund, and others have all backed the company.

Video On Demand

– Recorded

February 7

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.